Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

ORATORIO Clinical Investigators, Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki GarrenNicole Mairon, Peter Chin, Jerry S Wolinsky, Peter Wipfler (Study group member)

Research output: Contribution to journalOriginal Articlepeer-review

1191 Citations (Web of Science)
Original languageEnglish
Pages (from-to)209-220
JournalNEW ENGLAND JOURNAL OF MEDICINE
Volume376
Issue number3
DOIs
Publication statusPublished - 2017

Keywords

  • DOUBLE-BLIND
  • MULTICENTER TRIAL
  • CANCER-RISK
  • CD20
  • DEMYELINATION
  • PATHOLOGY
  • ANTIBODY
  • DAMAGE

Cite this